Navigation Links
EntreMed Presents Initial Clinical Results for ENMD-2076
Date:2/9/2009

Orphan Drug Designation and Canadian CTA Accelerate ENMD-2076 Program Momentum

ROCKVILLE, Md., Feb. 9 /PRNewswire-FirstCall/ -- EntreMed, Inc. (Nasdaq: ENMD), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, today announced recent developments in its program for ENMD-2076, an Aurora A/angiogenic kinase inhibitor. These developments include the presentation of initial results for a Phase 1 study in patients with refractory solid tumors as well as preclinical data showing significant potential for the use of ENMD-2076 in combination with platinum-based chemotherapy in breast cancer. In addition, EntreMed has received an Orphan Drug Designation from the FDA for the treatment of multiple myeloma using ENMD-2076. To further enhance its clinical development efforts for the drug candidate, a No Objection Letter was received by EntreMed from Health Canada permitting ENMD-2076 to be used in clinical trials within Canada. Data for the Phase 1 study in solid tumors, which is being conducted at the University of Colorado Cancer Center and the Dana-Farber Cancer Institute, were presented by Jennifer Diamond, M.D., during an oral presentation at the 11th International Symposium on Anti-Angiogenic Agents held last week in San Diego, California. Dr. Diamond is a Hematology/Oncology Fellow, working in the Developmental Therapeutics Program of the University of Colorado.

(Logo: http://www.newscom.com/cgi-bin/prnh/20010620/ENMDLOGO )

Results from the ongoing Phase 1 study in patients with refractory solid tumors demonstrated that ENMD-2076 administered orally in 28-day cycles was well tolerated. Data show preliminary evidence of antitumor activity as determ
'/>"/>

SOURCE EntreMed, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. EntreMed Presents Data for Phase 2 Study of MKC-1 in Metastatic Breast Cancer
2. EntreMed Raises $20 Million to Support Clinical Development Program
3. EntreMed Reports Phase 1 PK and Preclinical Efficacy Results for ENMD-1198
4. EntreMed Shows Increased Survival With MKC-1 in Preclinical Renal Cell Cancer Model
5. EntreMed Commences Phase 2 Study with MKC-1 in Pancreatic Cancer
6. EntreMed to Present at The New York Society of Security Analysts Industry Conference
7. EntreMed Commences Phase 2 Study With MKC-1 in Ovarian/Endometrial Cancers
8. EntreMed Commences Continuous Dosing Clinical Trial For MKC-1
9. EntreMed Achieves a Key Milestone Through Initiation of ENMD-2076 Clinical Program
10. EntreMed to Highlight ENMD-2076 Kinase Inhibitor at 2008 AACR Annual Meeting
11. EntreMed Presents MKC-1 and ENMD-1198 Preclinical Data at AACR Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... Md. , Aug. 29, 2014  United Therapeutics ... the U.S. District Court for the District of ... favor in the company,s case against Sandoz, Inc. regarding ... Peter Sheridan ruled that U.S. Patent No. ... and enjoined Sandoz from marketing its generic product until ...
(Date:8/29/2014)... /PRNewswire-iReach/ -- ChemImage will present a workshop focused on ... Forensic Science Society,s 22 nd International Symposium ... Australia .  Forensic Scientists will be in ... imaging can bring to examination procedures. ... Product Development at ChemImage, will host a workshop ...
(Date:8/29/2014)... and MENLO PARK, Calif. ... Pharmaceuticals, Inc. (OTCQB: DMPI) ("DelMar" "the Company") today ... financial statements.  The Company recently changed its fiscal year ... application to list its common stock on a national ... DelMar,s financial statements as filed with the United States ...
Breaking Medicine Technology:District Court Decision Received In Remodulin Patent Case 2ChemImage to Discuss Hyperspectral Imaging for Forensic Investigation at the ANZFSS 22nd International Symposium on the Forensic Sciences 2ChemImage to Discuss Hyperspectral Imaging for Forensic Investigation at the ANZFSS 22nd International Symposium on the Forensic Sciences 3DelMar Pharmaceuticals Fiscal 2014 Year End Results and Summary of Recent Developments 2DelMar Pharmaceuticals Fiscal 2014 Year End Results and Summary of Recent Developments 3DelMar Pharmaceuticals Fiscal 2014 Year End Results and Summary of Recent Developments 4DelMar Pharmaceuticals Fiscal 2014 Year End Results and Summary of Recent Developments 5
... patients will be tested,to determine the prevalence of ... major cooperative effort between the Alpha-1 Foundation,and the ... principal investigator is Robert A. Sandhaus, MD, PhD, ... and Research Center,in Denver. Sandhaus is also the ...
... Dec. 6 DURECT Corporation,(Nasdaq: DRRX ... III trial for Remoxy,had successfully met its ... the U.S. Food and Drug Administration (FDA) ... investigational drug based on,DURECT,s patented ORADUR(TM) technology, ...
Cached Medicine Technology:Alpha-1 Foundation, AARC Cooperate on Study to Test 5,000 COPD Patients for Alpha-1 2Alpha-1 Foundation, AARC Cooperate on Study to Test 5,000 COPD Patients for Alpha-1 3Primary Endpoint of Pivotal Phase III Clinical Trial Achieved for Remoxy(TM) 2Primary Endpoint of Pivotal Phase III Clinical Trial Achieved for Remoxy(TM) 3Primary Endpoint of Pivotal Phase III Clinical Trial Achieved for Remoxy(TM) 4
(Date:8/30/2014)... Daily Gossip reveals in its recently published review that ... by Sarah Summer, who can perfectly understand what suffering from ... program actually had to deal with this disorder, too. Her ... access it, in an all-natural holistic cure program. , So, ... cure for yeast infection. The author of this program suffered ...
(Date:8/30/2014)... NY (PRWEB) August 30, 2014 ... U.S. Open Tennis Championship tickets in NYC. ... appreciation promo/coupon code US-OPEN-2014 for all day session, evening ... and group sales for this prestigious Grand Slam Tournament. ... below: , 8/30/14 , US Open Tennis Championship: Men's/Women's ...
(Date:8/30/2014)... Market Research Report on Global ... professional and in-depth market survey on Global and ... the basic information of Cell Disruptor including its ... explores global and China’s top manufacturers of Cell ... and market share etc. The report further analyzes ...
(Date:8/30/2014)... Continuing to meet the skin health ... the addition of a new doctor and office in ... leading-edge skin care in Grand Rapids since 1980 is ... a doctor, my passion is making sure my patients ... Dermatology, I’m better able to focus on my patients ...
(Date:8/30/2014)... "My wife suffered neck, back and ... said one of two inventors from Bethel, Alaska. "The ... and neck area. She tried other pillows to little ... assisting in comfort and providing extra sleep." , They ... support the head, neck and back comfortably. This enables ...
Breaking Medicine News(10 mins):Health News:Natural Cure for Yeast Infection Review Exposes New Natural Treatment 2Health News:US Open Tennis Tickets: Ticket Down Slashes Ticket Prices for Labor Day Weekend Sessions and More 2Health News:US Open Tennis Tickets: Ticket Down Slashes Ticket Prices for Labor Day Weekend Sessions and More 3Health News:US Open Tennis Tickets: Ticket Down Slashes Ticket Prices for Labor Day Weekend Sessions and More 4Health News:US Open Tennis Tickets: Ticket Down Slashes Ticket Prices for Labor Day Weekend Sessions and More 5Health News:Cell Disruptor Industry Global and Chinese Analysis for 2009-2019 in New Research Report at ReportsnReports.com 2Health News:Cell Disruptor Industry Global and Chinese Analysis for 2009-2019 in New Research Report at ReportsnReports.com 3Health News:Cell Disruptor Industry Global and Chinese Analysis for 2009-2019 in New Research Report at ReportsnReports.com 4Health News:Expanding Care at the Forefront of Dermatology 2
... global outbreak of the SWINE FLU and Mexico representing ... combat the continued spread of the unpredictable virus. U.S. ... a Combatant.There is now an outstanding scientific formula to ... TUBERCULOCIDAL AND FUNGICIDE" that is formulated to deal ...
... Program to Launch at the Annual Oncology Nursing Society ... ONS Edge , a subsidiary of the Oncology Nursing ... celebrity make-up artist and cancer survivor Jan Ping to ... From the Outside In . The initiative is aimed ...
... 2009 Biogen Idec (NASDAQ: BIIB) today announced data ... Multiple Sclerosis (MS) Prevention Study In Ongoing Neurologic Surveillance) ... Risk Subjects AVONEX MS Prevention Study). Based on ... in patients who experienced their first clinical MS episode ...
... Launches Women of Hope is Beautiful Campaign to Inspire OthersWASHINGTON, ... control, community, caring -- ask any woman who has ... these words. They are also integral to Look ... to help women cope with the appearance-related changes of cancer ...
... Driving Increased Utilization of ePrescribing within Electronic ... Tullman Testifies Before National Committee on Vital ... announced today that, for the second consecutive ... the Surescripts network than any other e-prescribing ...
... residents Access to Nursing Home, Assisted Living, Home Care and ... Statewide RICHMOND, Va., April 30 The cost ... rate outpacing inflation, putting significant financial pressure on those in ... Financial. At the same time, the current economic downturn ...
Cached Medicine News:Health News:USC Chemical Engineer Launches Virucide, Bactericidal That Can Kill 99.9% of Germs and Help Combat Swine Flu 2Health News:Amgen and ONSEdge Partner With Cancer Survivor Jan Ping for New Campaign 2Health News:Amgen and ONSEdge Partner With Cancer Survivor Jan Ping for New Campaign 3Health News:First ten-year follow-up shows that treatment with AVONEX leads to long-term benefits in early multiple sclerosis patients 2Health News:Photos: Look Good. . .Feel Better Celebrates 20 Years of Helping Women Cope With Cancer 2Health News:Photos: Look Good. . .Feel Better Celebrates 20 Years of Helping Women Cope With Cancer 3Health News:Photos: Look Good. . .Feel Better Celebrates 20 Years of Helping Women Cope With Cancer 4Health News:Allscripts Ranked No. 1 in Electronic Prescription Routing for Second Consecutive Year 2Health News:Allscripts Ranked No. 1 in Electronic Prescription Routing for Second Consecutive Year 3Health News:Allscripts Ranked No. 1 in Electronic Prescription Routing for Second Consecutive Year 4Health News:Allscripts Ranked No. 1 in Electronic Prescription Routing for Second Consecutive Year 5Health News:Allscripts Ranked No. 1 in Electronic Prescription Routing for Second Consecutive Year 6Health News:Growth in Wisconsin Long Term Care Costs Outpacing the Rate of Inflation, According to Annual Genworth Financial Study 2Health News:Growth in Wisconsin Long Term Care Costs Outpacing the Rate of Inflation, According to Annual Genworth Financial Study 3Health News:Growth in Wisconsin Long Term Care Costs Outpacing the Rate of Inflation, According to Annual Genworth Financial Study 4
... Pipette Tracker Pro is the only pipette calibration ... regulated environment with the tools that they need ... All of the features of Pipette Tracker ... Full audit trail implementation Support for Oracle ...
... V-shaped bottom allows easy withdrawal of ... per bag, ,• Corner pouring lips ... Basin designed for 4, 8, and 12 ... bottom permits withdrawal of practically all of ...
Reservoir, High Profile, Multi Well, 12 Row, Pyramid Bottom, 21mL Available Sterile...
Reservoir, High Profile, Single Well, 96ch-format, Pyramid Bottom, 240mL Available Sterile...
Medicine Products: